



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SHEN *et al.*

Appl. No.: 09/845,153

Filed: May 1, 2001

For: **Methods and Compositions for  
Lipidization of Hydrophilic  
Molecules**

Confirmation No.: 4085

Art Unit: 1653

Examiner: Desai, A.U.

Atty. Docket: 1696.0020008/RWE/BSA

**Fourth Supplemental Information Disclosure Statement**

**Under 37 C.F.R. § 1.97(b)**

*Mail Stop 313(c)*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on September 13, 2005 in connection with the above-captioned application. Copies of documents AT23 to AR24 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Form based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being before the mailing of a first Office action after the filing of a request for continued examination (RCE) under § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: Jan 17, 2006

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/845,153
				Filing Date	May 1, 2001
				First Named Inventor	Wei-Chiang SHEN
				Art Unit	1653
				Examiner Name	Desai, A.U.
Sheet	1	of	1	Attorney Docket Number	1696.0020008/RWE/BSA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AT23	Boehm, J.C. and Kingsbury, W.D., "The Use of Cysteinyl Peptides to Effect Portage Transport of Sulfhydryl-containing Compounds in <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 258:14850-14855, The American Society for Biological Chemists, Inc. (1983)	
	AR24	Dhanasekaran, N., <i>et al.</i> , "Mapping of the Carboxyl Terminus within the Tertiary Structure of Transducin's $\alpha$ Subunit Using the Heterobifunctional Cross-linking Reagent, <sup>125</sup> I-N-(3-Iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)cysteine," <i>J. Biol. Chem.</i> 263:17942-17950, The American Society for Biological Chemists, Inc. (1988)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.